Connor, Clark & Lunn Investment Management (CC&L)’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-576,354
| Closed | -$1.31M | – | 1696 |
|
|
2024
Q2 | $1.31M | Buy |
576,354
+162,775
| +39% | +$371K | 0.01% | 780 |
|
|
2024
Q1 | $1.79M | Buy |
413,579
+221,469
| +115% | +$957K | 0.01% | 705 |
|
|
2023
Q4 | $586K | Sell |
192,110
-12,090
| -6% | -$36.9K | ﹤0.01% | 999 |
|
|
2023
Q3 | $294K | Buy |
204,200
+82,879
| +68% | +$119K | ﹤0.01% | 1149 |
|
|
2023
Q2 | $302K | Buy |
121,321
+104,808
| +635% | +$261K | ﹤0.01% | 1104 |
|
|
2023
Q1 | $44.3K | Buy |
+16,513
| New | +$44.3K | ﹤0.01% | 1195 |
|
|
2022
Q4 | – | Sell |
-90,139
| Closed | -$1.13M | – | 1469 |
|
|
2022
Q3 | $1.13M | Buy |
90,139
+50,481
| +127% | +$631K | 0.01% | 627 |
|
|
2022
Q2 | $196K | Buy |
+39,658
| New | +$196K | ﹤0.01% | 938 |
|
|
2021
Q4 | – | Sell |
-26,211
| Closed | -$352K | – | 1236 |
|
|
2021
Q3 | $352K | Buy |
+26,211
| New | +$352K | ﹤0.01% | 840 |
|
|
2021
Q1 | – | Sell |
-23,330
| Closed | -$420K | – | 1118 |
|
|
2020
Q4 | $420K | Buy |
+23,330
| New | +$420K | ﹤0.01% | 745 |
|